Biologic therapies targeting eosinophils: current status and future prospects.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25754717.
- Also identified by DOI 10.1016/j.jaip.2015.01.013 and PMC identifier 4418449.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders.
Medical subject headings
- Biological Therapy
- Eosinophils
- Immune System Diseases